H. Lundbeck A/S HLBBF
7.10 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
7.10 Day range 7.10
5.70 52-week range 7.29
- YTD
- +3.50%
- 1 year
- +3.65%
News
seekingalpha.com H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
seekingalpha.com H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
seekingalpha.com H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
seekingalpha.com H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
wsj.com H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
seekingalpha.com H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript H. Lundbeck A/S (OTCPK:HLBBF) Q3 2025 Earnings Call November 12, 2025 7:00 AM EST Company Participants Charl van Zyl - President & CEO Thomas Gibbs - Executive VP & Head of Lundbeck in United States…
prnewswire.com Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a…